keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer progression

keyword
https://www.readbyqxmd.com/read/28454436/satb1-promotes-epithelial-mesenchymal-transition-and-metastasis-in-prostate-cancer
#1
Honggang Qi, Xinyang Fu, Yeping Li, Xiang Pang, Sansan Chen, Xiaojun Zhu, Fei Li, Wanlong Tan
Special AT-rich sequence-binding protein-1 (SATB1) is associated with cancer progression and poor clinical outcome. The present study aims to evaluate whether SATB1 affects the biological behaviors of prostate cancer (PCa), and furthermore, to elucidate whether this effect works through the epithelial-mesenchymal transition (EMT) pathway. Firstly, the expression of SATB1 was investigated in a series of PCa tissues as well as in a panel of PCa cell lines. Cell proliferation, migration and invasion were evaluated in SATB1 knockdown and overexpressed PCa cell lines by MTT and Transwell assays...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454349/low-serum-testosterone-is-associated-with-tumor-aggressiveness-and-poor-prognosis-in-prostate-cancer
#2
Huakang Tu, Jian Gu, Qing H Meng, Jeri Kim, Sara Strom, John W Davis, Yonggang He, Elizabeth A Wagar, Timothy C Thompson, Christopher J Logothetis, Xifeng Wu
Serum testosterone is a potential marker to distinguish between indolent and aggressive prostate cancer (PCa). The present study aimed to investigate whether low levels of total serum testosterone at diagnosis were associated with aggressive PCa and poor clinical outcomes. In total, 762 non-Hispanic Caucasian men with previously untreated PCa were recruited from The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Patients were categorized into three groups based on their total serum testosterone levels according to clinical guidelines [low (<230 ng/dl), intermediate (230-350 ng/dl) and normal (>350 ng/dl)]...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28449007/efficacy-of-stereotactic-body-radiotherapy-in-oligorecurrent-and-in-oligoprogressive-prostate-cancer-new-evidence-from-a-multicentric-study
#3
Luca Triggiani, Filippo Alongi, Michela Buglione, Beatrice Detti, Riccardo Santoni, Alessio Bruni, Ernesto Maranzano, Frank Lohr, Rolando D'Angelillo, Alessandro Magli, Alberto Bonetta, Rosario Mazzola, Nadia Pasinetti, Giulio Francolini, Gianluca Ingrosso, Fabio Trippa, Sergio Fersino, Paolo Borghetti, Paolo Ghirardelli, Stefano Maria Magrini
BACKGROUND: The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC). METHODS: Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT)...
April 27, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28448495/dysregulation-of-inf2-mediated-mitochondrial-fission-in-spop-mutated-prostate-cancer
#4
Xiaofeng Jin, Jie Wang, Kun Gao, Pingzhao Zhang, Longfang Yao, Yan Tang, Lisha Tang, Jian Ma, Jiantao Xiao, Enceng Zhang, Jie Zhu, Bin Zhang, Shi-Min Zhao, Yao Li, Shancheng Ren, Haojie Huang, Long Yu, Chenji Wang
Next-generation sequencing of the exome and genome of prostate cancers has identified numerous genetic alternations. SPOP (Speckle-type POZ Protein) was one of the most frequently mutated genes in primary prostate cancer, suggesting SPOP is a potential driver of prostate cancer development and progression. However, how SPOP mutations contribute to prostate cancer pathogenesis remains poorly understood. SPOP acts as an adaptor protein of the CUL3-RBX1 E3 ubiquitin ligase complex that generally recruits substrates for ubiquitination and subsequent degradation...
April 27, 2017: PLoS Genetics
https://www.readbyqxmd.com/read/28447434/the-influence-of-different-muscle-mass-measurements-on-the-diagnosis-of-cancer-cachexia
#5
Susanne Blauwhoff-Buskermolen, Jacqueline A E Langius, Annemarie Becker, Henk M W Verheul, Marian A E de van der Schueren
BACKGROUND: Progressive loss of muscle mass is a major characteristic of cancer cachexia. Consensus definitions for cachexia provide different options to measure muscle mass. This study describes the effect of different methods to determine muscle mass on the diagnosis of cancer cachexia. In addition, the association of cachexia with other features of cachexia, quality of life, and survival was explored. METHODS: Prior to chemotherapy, cachexia was assessed by weight loss, body mass index, and muscle mass measurements, the latter by mid-upper arm muscle area (MUAMA), computed tomography (CT) scans, and bio-electrical impedance analysis (BIA)...
April 26, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28446230/label-retention-and-stem-cell-marker-expression-in-the-developing-and-adult-prostate-identifies-basal-and-luminal-epithelial-stem-cell-subpopulations
#6
Jens Adam Ceder, Tilly Wilhelmina Aalders, Jack Antonius Schalken
BACKGROUND: Prostate cancer is the second most frequent cancer among males worldwide, and most patients with metastatic disease eventually develop therapy-resistant disease. Recent research has suggested the existence of cancer stem-like cells, and that such cells are behind the therapy resistance and progression. METHODS: Here, we have taken advantage of the relatively quiescent nature of stem cells to identify the slow-cycling label-retaining stem cell (LRC) populations of the prostate gland...
April 26, 2017: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/28445135/micrornas-in-prostate-cancer-an-overview
#7
REVIEW
Daniela Vanacore, Mariarosaria Boccellino, Sabrina Rossetti, Carla Cavaliere, Carmine D'Aniello, Rossella Di Franco, Francesco Jacopo Romano, Micaela Montanari, Elvira La Mantia, Raffaele Piscitelli, Flavia Nocerino, Francesca Cappuccio, Giovanni Grimaldi, Alessandro Izzo, Luigi Castaldo, Maria Filomena Pepe, Maria Gabriella Malzone, Gelsomina Iovane, Gianluca Ametrano, Paola Stiuso, Lucio Quagliuolo, Daniela Barberio, Sisto Perdonà, Paolo Muto, Maurizio Montella, Piera Maiolino, Bianca Maria Veneziani, Gerardo Botti, Michele Caraglia, Gaetano Facchini
Prostate cancer is the second highest cause of cancer mortality after lung tumours. In USA it affects about 2.8 million men and the incidence increases with age in many countries. Therefore, early diagnosis is a very important step for patient clinical evaluation and for a selective and efficient therapy. The study of miRNAs' functions and molecular mechanisms has brought new knowledge in biological processes of cancer. In prostate cancer there is a deregulation of several miRNAs that may function as tumour suppressors or oncogenes...
April 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28444169/androgen-receptor-regulation-of-local-growth-hormone-in-prostate-cancer-cells
#8
M V Recouvreux, B Wu, A C Gao, S Zonis, V Chesnokova, N Bhowmick, L W Chung, S Melmed
Prostate cancer (PCa) growth is mainly driven by androgen receptor (AR), and tumors that initially respond to androgen deprivation therapy (ADT) or AR inhibition usually relapse into a more aggressive, castration resistant stage (CRPC). Circulating growth hormone (GH) has a permissive role in PCa development in animal models and in human PCa xenograft growth. As GH and GH receptor (GHR) are both expressed in PCa cells, we assessed whether prostatic GH production is linked to AR activity and whether GH contributes to the castration resistant phenotype...
April 21, 2017: Endocrinology
https://www.readbyqxmd.com/read/28443495/aldh1a3-correlates-with-luminal-phenotype-in-prostate-cancer
#9
Shangqian Wang, Chao Liang, Meiling Bao, Xiao Li, Lei Zhang, Shuang Li, Chao Qin, Pengfei Shao, Jie Li, Lixin Hua, Zengjun Wang
Prostate cancer is the most common male malignancies in the United States. The specific characteristics of different disease stages have been deeply investigated. We present our data on ALDH1A3 as a potential therapeutic target for the prostate cancer based on several functional investigations. Also, we used The Cancer Genome Atlas datasets for primary prostate cancer to detect the relevance of ALDH1A3 and prostate cancer luminal phenotype. We found that ALDH1A3 correlated with androgen receptor signaling pathway in primary prostate cancer, which is consistent with its luminal layer localization...
April 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28443242/incidental-leydig-cell-tumor-in-patient-with-hormone-resistant-prostate-cancer
#10
M Sánchez Pérez, P Jiménez Marrero, D Kim Lee, M P Neumann, N Jorge Pérez, C Hernández Hernández, S Hernández Escobar, R Marrero Domínguez
We hereby present the case of a 55 years old patient with clinical diagnosis of high-risk prostate cancer T2bN1Mo Gleason 9 (4 + 5) treated with androgen deprivation therapy and external beam radiotherapy. Despite treatment, castration levels were not achieved and clinical progression was evidenced by the appearance of bone metastases and progression of PSA. After several hormonal treatments without any PSA or testosterone response, surgical castration was performed by bilateral orchiectomy. The pathology results showed an incidental Leydig cell tumor in the right testicle...
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28443139/maximal-testosterone-suppression-in-the-management-of-recurrent-and-metastatic-prostate-cancer
#11
REVIEW
Laurence Klotz, Rodney H Breau, Loretta L Collins, Martin E Gleave, Tom Pickles, Frederic Pouliot, Fred Saad
INTRODUCTION: Testosterone suppression, or androgen-deprivation therapy (ADT), is an established treatment for recurrent and metastatic prostate cancer (PCa). Based on the accuracy and sensitivity of early assays (c. 1960-1970), the castrate testosterone level was set at ≤1.7 nmol/l. Improved sensitivity of testosterone assays shows that both surgical and medical castration can achieve levels <0.7 nmol/l. However, the clinical implications and importance of maximum testosterone suppression remains a subject of controversy...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28442907/synthesis-of-magnetic-molecularly-imprinted-polymers-with-excellent-biocompatibility-for-the-selective-separation-and-inhibition-of-testosterone-in-prostate-cancer-cells
#12
Xiaoshuang Tang, Feng Li, Jing Jia, Chao Yang, Wei Liu, Ben Jin, Xinyang Wang, Ruixia Gao, Dalin He, Peng Guo
PURPOSE: Androgen plays an important role in the progression of prostate cancer. In the present study, novel magnetic molecularly imprinted polymers (MMIPs) with good biocompatibility were produced for the selective separation and inhibition of testosterone in prostate cancer cells. MATERIALS AND METHODS: MMIPs were prepared by using magnetic nanospheres, gelatin, and testosterone as the supporting materials, functional monomer, and the template molecule, respectively...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28441112/second-line-hormonal-therapy-for-men-with-chemotherapy-na%C3%A3-ve-castration-resistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion
#13
Katherine S Virgo, Ethan Basch, D Andrew Loblaw, Tom Oliver, R Bryan Rumble, Michael A Carducci, Luke Nordquist, Mary-Ellen Taplin, Eric Winquist, Eric A Singer
Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publication or presentation of potential practice-changing data. This PCO addresses second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer (CRPC) who range from being asymptomatic with only biochemical evidence of CRPC to having documented metastases but minimal symptoms. Clinical Context The treatment goal for CRPC is palliation. Despite resistance to initial androgen deprivation therapy, most men respond to second-line hormonal therapies...
April 25, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28440478/overexpression-of-secretory-phospholipase-a2-iia-supports-cancer-stem-cell-phenotype-via-her-erbb-elicited-signaling-in-lung-and-prostate-cancer-cells
#14
Shan Lu, Zhongyun Dong
Resistance to conventional chemotherapies remains a significant clinical challenge in treatment of cancer. The cancer stem cells (CSCs) have properties necessary for tumor initiation, resistance to therapy, and progression. HER/ERBB‑elicited signaling supports CSC properties. Our previous studies revealed that secretory phospholipase A2 group IIa (sPLA2‑IIa) is overexpressed in both prostate and lung cancer cells, leading to an aberrant high level in the interstitial fluid, i.e., tumor microenvironment and blood...
April 19, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28440434/preclinical-studies-for-the-combination-of-paclitaxel-and-curcumin-in-cancer-therapy-review
#15
Yumeng Wei, Xinlin Pu, Ling Zhao
Cancer is one of the most common causes of death and remains the first in China and the second in the US. The common treatments for cancer include surgery, radiation, chemotherapy, targeted therapy and immunotherapy, while chemotherapy remains one of the most important treatments. However, the efficacy of chemotherapy is limited due to drug induced-toxicities and resistance, particularly multiple drug resistance (MDR). Therefore, discovery and development of novel therapeutic drugs and/or combination therapy are urgently needed to reduce toxicity and improve efficacy...
April 20, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28439009/estrogen-receptor-%C3%AE-a-regulator-of-androgen-receptor-signaling-in-the-mouse-ventral-prostate
#16
Wan-Fu Wu, Laure Maneix, Jose Insunza, Ivan Nalvarte, Per Antonson, Juha Kere, Nancy Yiu-Lin Yu, Virpi Tohonen, Shintaro Katayama, Elisabet Einarsdottir, Kaarel Krjutskov, Yu-Bing Dai, Bo Huang, Wen Su, Margaret Warner, Jan-Åke Gustafsson
As estrogen receptor β(-/-) (ERβ(-/-)) mice age, the ventral prostate (VP) develops increased numbers of hyperplastic, fibroplastic lesions and inflammatory cells. To identify genes involved in these changes, we used RNA sequencing and immunohistochemistry to compare gene expression profiles in the VP of young (2-mo-old) and aging (18-mo-old) ERβ(-/-) mice and their WT littermates. We also treated young and old WT mice with an ERβ-selective agonist and evaluated protein expression. The most significant findings were that ERβ down-regulates androgen receptor (AR) signaling and up-regulates the tumor suppressor phosphatase and tensin homolog (PTEN)...
April 24, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28437789/comparative-proteomics-uncovers-correlated-signaling-network-and-potential-biomarkers-for-progression-of-prostate-cancer
#17
Jianzhong Ai, Yi Lu, Qiang Wei, Hong Li
BACKGROUND/AIMS: Prostate cancer is one of the most common cancers for males worldwide, and it is prone to show the metastatic foci in lymph node and bone with high mortality. To date, the potential mechanism and the corresponding biomarkers for metastatic prostate cancer are still lacking. Hence, our study aims to clarify the mechanism of prostate cancer progression and identify the useful biomarkers for metastatic prostate cancer. METHODS: The proteins and network tightly associated with tumor metastasis were identified using quantitative proteomics...
January 10, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28437038/impact-of-preoperative-risk-on-metastatic-progression-and-cancer-specific-death-in-patients-with-adverse-pathology-at-radical-prostatectomy
#18
Katharina Boehm, Sami-Ramzi Leyh-Bannurah, Clemens Rosenbaum, Laurenz S Brandi, Lars Budäus, Markus Graefen, Hartwig Huland, Axel Haferkamp, Derya Tilki
OBJECTIVE: To evaluate the impact of preoperative risk category on metastatic disease (MetD) and prostate cancer mortality (CSM) in prostate cancer (PCa) patients with adverse pathology at radical prostatectomy (RP). PATIENTS AND METHODS: The records of 6943 patients who underwent radical prostatectomy (RP) in a European tertiary-center were analysed. Biochemical recurrence (BCR), MetD and CSM were assessed for patients with adverse pathology at RP and stratified according to preoperative low- vs...
April 24, 2017: BJU International
https://www.readbyqxmd.com/read/28437029/the-men-s-eating-and-living-meal-study-calgb-70807-alliance-recruitment-feasibility-and-baseline-demographics-of-a-randomized-trial-of-diet-in-men-on-active-surveillance-for-prostate-cancer
#19
J Kellogg Parsons, John P Pierce, James Mohler, Electra Paskett, Sin-Ho Jung, Michael J Morris, Eric Small, Olwen Hahn, Peter Humphrey, John Taylor, James Marshall
OBJECTIVE: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. METHODS: The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) is a phase 3 clinical trial testing the efficacy of a high-vegetable diet to prevent progression in prostate cancer patients on active surveillance. Participants were randomized to a validated diet counseling intervention or a control condition. Chi-Square and Kruskal Wallis analyses were used to assess between-group differences at baseline...
April 24, 2017: BJU International
https://www.readbyqxmd.com/read/28436011/is-prostate-cancer-different-in-black-men-answers-from-3-natural-history-models
#20
Alex Tsodikov, Roman Gulati, Tiago M de Carvalho, Eveline A M Heijnsdijk, Rachel A Hunter-Merrill, Angela B Mariotto, Harry J de Koning, Ruth Etzioni
BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000...
April 24, 2017: Cancer
keyword
keyword
58390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"